Valor Compounding Pharmacy Inc. Berkeley, CA. Untitled Letter issued 03 23 2023 The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide What Is BPC 157? A Medical Clinic's Guide to the Body Protective Peptide, Its Uses, and What It Actually Does Perfect B On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver FDA's Overreach on Compounded Peptides